Plasma-Treated Liquid for Atopic Dermatitis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for atopic dermatitis and psoriasis are inadequate due to temporary efficacy and significant side effects, and there is a need for a therapeutic agent that can effectively inhibit immune hypersensitivity reactions and chronic inflammatory responses.

Innovation Solution

The development of plasma-treated liquid material, produced by non-thermal atmospheric pressure plasma, which inhibits the activity of mast cells, STAT6, and NF-kB, and is used to create a pharmaceutical composition for treating atopic dermatitis and psoriasis, offering a method for preventing or treating these conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If steroids and immunosuppressants are used to treat atopic dermatitis, then treatment efficacy is improved, but side effects increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces plasma-treated liquid material as an intermediary substance that mediates the treatment effect. This material contains plasma-generated reactive species and cytokines that indirectly modulate the immune response and reduce inflammation, rather than directly suppressing immunity like steroids. The plasma-treated liquid acts as a carrier of therapeutic factors that alleviate symptoms without causing the severe side effects of conventional drugs.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the chemical/pharmacological mechanism of steroids and immunosuppressants with a plasma-based physical treatment mechanism. Low-temperature plasma generates reactive oxygen species, nitrogen species, and other bioactive molecules that physically and chemically interact with skin cells and immune cells to reduce inflammation. This substitution of treatment mechanism eliminates the need for harmful chemical suppressants while maintaining therapeutic efficacy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Duration of action of moving object

If conventional treatments are used for atopic dermatitis, then symptoms are temporarily relieved, but treatment duration is limited

Engineering Contradiction:

Improvetreatment durationVSAvoidtherapeutic effect duration

Core Design Contradiction:

Duration of action of moving objectVSDuration of action of stationary object

Solution Approach 1:

The plasma-treated liquid material contains pre-generated reactive species and anti-inflammatory cytokines that are prepared in advance through plasma treatment. When applied to the skin, these pre-formed therapeutic factors immediately begin acting on inflammatory cells and pathways, providing sustained relief. The plasma treatment process creates a reservoir of stable bioactive molecules that continue to exert therapeutic effects over an extended period, rather than providing only temporary symptom relief.

Inventive Principle:

Principle #10Preliminary action

3Object-affected harmful factors

If plasma-treated liquid material is used to treat atopic dermatitis, then side effects are reduced, but treatment mechanism complexity increases

Engineering Contradiction:

Improveside effectsVSAvoidtreatment mechanism complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the beneficial therapeutic components (reactive oxygen species, nitrogen species, cytokines, and other bioactive molecules) generated by plasma treatment into a liquid material formulation. This extraction separates the therapeutic factors from the complex plasma generation apparatus, allowing the treatment mechanism to be simplified to topical application of the prepared liquid. The complex plasma processing is performed once during manufacturing, and the resulting stable liquid product can be easily applied without requiring complex treatment equipment.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The plasma-treated liquid material effectively alleviates symptoms of atopic dermatitis and psoriasis by inhibiting immune hypersensitivity reactions and reducing inflammatory cytokines, providing a sustainable treatment with fewer side effects compared to existing therapies.

Implementation Method 1

plasma-treated liquid material, produced by non-thermal atmospheric pressure plasma

Methodology Applied

Scientific EffectPlasma: Plasma

Implementation Method 2

produced by non-thermal atmospheric pressure plasma

Methodology Applied

Scientific EffectNon-thermal atmospheric pressure plasma: Plasma

Data Source

PatentUS11583689B2Composition for atopy or psoriasis treatment comprising liquid type plasma

Publication Date: 2023.02.21 AJOU UNIV IND ACADEMIC COOP FOUND

AI summary

The present invention relates to a composition for atopy or psoriasis treatment comprising a plasma-treated liquid material. More particularly, the present invention relates to a method for producing a plasma-treated liquid material for preventing or treating atopic dermatitis or psoriasis, a pharmaceutical composition for preventing or treating a topic dermatitis or psoriasis using a plasma-treated liquid material produced according to the method, and a method for preventing or treating atopic dermatitis or psoriasis using the plasma-treated liquid material.